TCGA-E2-A570-01A-11R-A29R-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 31
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
- ESTROGEN_RESPONSE_LATE+0.200
- MYOGENESIS+0.180
- HEDGEHOG_SIGNALING+0.160
- ESTROGEN_RESPONSE_EARLY+0.150
- OXIDATIVE_PHOSPHORYLATION+0.150
- P53_PATHWAY+0.100
- COAGULATION+0.090
- DNA_REPAIR+0.090
- APOPTOSIS+0.080
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.500
- IL6_JAK_STAT3_SIGNALING-0.460
- INTERFERON_GAMMA_RESPONSE-0.430
- UNFOLDED_PROTEIN_RESPONSE-0.420
- ALLOGRAFT_REJECTION-0.410
- MYC_TARGETS_V2-0.400
- INFLAMMATORY_RESPONSE-0.350
- G2M_CHECKPOINT-0.340
- MTORC1_SIGNALING-0.340
- MITOTIC_SPINDLE-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OL-A66K-01A-11R-A29R-07 | — | B | 0.860 |
| 2 | TCGA-A7-A5ZX-01A-12R-A29R-07 | — | A | 0.835 |
| 3 | TCGA-IQ-7631-01A-11R-2081-07 | — | — | 0.835 |
| 4 | TCGA-AR-A5QP-01A-11R-A28M-07 | — | A | 0.818 |
| 5 | TCGA-W8-A86G-01A-21R-A36F-07 | — | A | 0.813 |
| 6 | SRR5088900 | — | — | 0.811 |
| 7 | TCGA-D8-A73X-01A-11R-A32P-07 | — | B | 0.806 |
| 8 | TCGA-AC-A3W7-01A-11R-A22K-07 | — | A | 0.799 |
| 9 | s0095179 | — | — | 0.797 |
| 10 | SRR23036896 | — | — | 0.797 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.150 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| COAGULATION | 0.090 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.090 | Idelalisib | — uncovered |
| APOPTOSIS | 0.080 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.040 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.030 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.010 | Inavolisib | — uncovered |